ADC Therapeutics Q2 2024 Adj. EPS $(0.25) Beats $(0.46) Estimate, Sales $17.410M Miss $18.798M Estimate
Portfolio Pulse from Benzinga Newsdesk
ADC Therapeutics reported Q2 2024 adjusted EPS of $(0.25), beating the estimate of $(0.46). However, sales were $17.410 million, missing the estimate of $18.798 million.
August 06, 2024 | 11:32 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
ADC Therapeutics reported better-than-expected Q2 2024 adjusted EPS of $(0.25) compared to the $(0.46) estimate, but missed sales estimates with $17.410 million versus $18.798 million expected.
The better-than-expected EPS is a positive sign, indicating cost management or other efficiencies. However, the miss on sales could raise concerns about revenue growth. The mixed results may lead to neutral short-term price movement as investors weigh the positives and negatives.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100